Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Next Generation Conjugate Summit

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Jan 30, 2024 3:38pm

53 Views

Post# 35853394

RE:Next Generation Conjugate Summit

JFM - Does this suggest to you that they may be taking your advice?

scarlet1967 wrote:
Christian Marsolais - Next-Generation Conjugates Summit

Christian Marsolais - Next-Generation Conjugates Summit

This is a new added presentation and it wasn't listed before. Apart from immunotherapy part attaching two payloads, he will be talking about diagnostic imaging using radioactive agents!!

About Singzyme:

Innovative Technology

The core technology of the platform lies in the use of Peptide Asparaginyl Ligases (PALs) to conjugate active drugs or any other payloads to proteins.

Singzyme's platform for antibodies and nanobodies engineering and conjugation provides a one- stop solution to the problems faced by Antibody Drug Conjugates developers, stemming from their manufacturing process. Singzyme provides an integrated, high-speed, precision bio-manufacturing platform for ADCs and other bioconjugates.

https://singzyme.com/

His added presentation day one:

Describing how Singzyme provides a one-stop solution for antibodies and nanobodies engineering and conjugation

Exploring how Singzyme’s technology accelerates the development of cancer immunotherapy, allowing faster production of antibody-drug-conjugates with minimal footprint on the final product and the possibility to attach two payloads with a defined DAR

Exploring Singzyme’s technology which allows imaging for disease diagnosis: production of radiopharmaceuticals for PET scan

imaging (Nanobodies or mAbs) with minimal radioactive waste thanks to the highest conjugation efficiency on the market